- PR Newswire•13 hours ago
THOUSAND OAKS, Calif., April 24, 2017 /PRNewswire/ -- Amgen (AMGN) today announced an expanded commercial collaboration with Novartis for erenumab, which is being investigated for the prevention of migraine. This expanded commercial collaboration builds on a global neuroscience collaboration in Alzheimer's disease and migraine established in 2015 between Novartis and Amgen. This expanded collaboration leverages Novartis' strong and established presence in neuroscience to more effectively reach people with migraine.
- MarketWatch•13 hours ago
The drugmaker could face a mixed quarter, analysts say.
- Barrons.com•15 hours ago
Top holdings Biogen (BIIB) and Amgen (AMGN) have gained 1.95% and 1.56% ahead of earnings results, respectively. Alliance Bernstein analyst Ronny Gal has an Outperform rating on Biogen with a price target of $310, implying an upside of 12% from its recent price of $277. Gal details three things to watch for when Biogen reports tomorrow: MS sales.
AMGN : Summary for Amgen Inc. - Yahoo Finance
Amgen Inc. (AMGN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||163.23 x 100|
|Ask||164.40 x 300|
|Day's Range||161.91 - 163.60|
|52 Week Range||133.64 - 184.21|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||15.93|
|Dividend & Yield||4.60 (2.84%)|
|1y Target Est||N/A|